AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
Improves Overall Survival In Liver Cancer Patients
Executive Summary
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
You may also be interested in...
AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.
AstraZeneca Signs First COVID-19 Vaccine For-Profit Deals
AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.